FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Protagonist Therapeutics, Inc. - Common Stock
(NQ:
PTGX
)
140.06
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Protagonist Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
May 09, 2025
Via
ACCESS Newswire
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 06, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
April 23, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
April 16, 2025
Via
ACCESS Newswire
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study
↗
April 10, 2025
Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.
Via
Benzinga
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 21, 2025
Via
ACCESS Newswire
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
April 10, 2025
Via
ACCESS Newswire
Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy?
↗
April 05, 2025
Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX).
Via
Chartmill
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
March 18, 2025
Via
ACCESS Newswire
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
↗
March 16, 2025
Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.
Via
Benzinga
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
March 11, 2025
Via
Benzinga
Keep an eye on the top gainers and losers in Monday's session.
↗
March 10, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Monday's session: top gainers and losers
↗
March 10, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 10, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
↗
March 10, 2025
Via
Benzinga
Top movers in Monday's pre-market session
↗
March 10, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
↗
March 10, 2025
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.
Via
Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
↗
March 10, 2025
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.
Via
Investor's Business Daily
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
March 10, 2025
Via
ACCESS Newswire
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
March 08, 2025
Via
ACCESS Newswire
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
↗
March 03, 2025
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million.
Via
Benzinga
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
March 03, 2025
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a candidate for growth investors. Here's why.
↗
March 03, 2025
A fundamental analysis of (NASDAQ:PTGX): PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing high EPS and FCF growth while beating expectations
Via
Chartmill
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
January 29, 2025
Via
ACCESS Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
January 06, 2025
Via
ACCESSWIRE
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
December 19, 2024
Via
ACCESSWIRE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
December 09, 2024
Via
ACCESSWIRE
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
↗
November 22, 2024
Via
Benzinga
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
November 22, 2024
Via
ACCESSWIRE
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
November 21, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
